Abstract: A transdermal preparation comprising a multivalent metal chloride, a basic drug having an amino group, and an ester group-containing base material, is useful because of its excellent drug content stability.

Abstract: The present invention provides a patch having a backing and a pressure-sensitive adhesive layer on the backing, wherein the pressure-sensitive adhesive layer contains a pressure-sensitive adhesive base composed of a polymer having a hydroxyl group, a drug, polyvinylpyrrolidone and a multivalent metal chloride.

Abstract: The present subject matter provides a nail patch comprising a backing layer and a pressure-sensitive adhesive layer disposed on at least one side of the backing layer, wherein the pressure-sensitive adhesive layer comprises a pressure-sensitive adhesive base, terbinafine and/or a pharmacologically acceptable salt thereof, and sodium acetate and/or sorbitan monolaurate as a solubilizer.

Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylate-vinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.

Abstract: The present invention provides an adhesive patch for the treatment of tinea unguium intended to be applied once a day, comprising terbinafine and/or a pharmacologically acceptable salt thereof in an amount of 3 mg/cm2, wherein the adhesive patch is used so that the terbinafine concentration in nails may be 295±127 ng/mg and the terbinafine concentration in plasma may be 23 pg/mL or less, 8 weeks after the start of application, per cm2 of the patch size.

Abstract: Provided is a percutaneous absorption type formulation of a drug such as imidafenacin and silodosin, wherein stable absorption through the skin is realized. The percutaneous absorption type formulation containing a drug such as imidafenacin and silodosin further contains a transdermal absorption promoting agent, and fatty acid ester and/or fatty acid amide that further improve(s) the function of the transdermal absorption promoting agent.

Abstract: The present invention provides a patch having a backing and a pressure-sensitive adhesive layer on the backing, wherein the pressure-sensitive adhesive layer contains a pressure-sensitive adhesive base composed of a polymer having a hydroxyl group, a drug, polyvinylpyrrolidone and a multivalent metal chloride.

Abstract: A transdermal preparation comprising a multivalent metal chloride, a basic drug having an amino group, and an ester group-containing base material, is useful because of its excellent drug content stability.

Abstract: The present invention provides an adhesive patch for the treatment of tinea unguium intended to be applied once a day, comprising terbinafine and/or a pharmacologically acceptable salt thereof in an amount of 3 mg/cm2, wherein the adhesive patch is used so that the terbinafine concentration in nails may be 295±127 ng/mg and the terbinafine concentration in plasma may be 23 pg/mL or less, 8 weeks after the start of application, per cm2 of the patch size.

Abstract: The present subject matter provides a nail patch comprising a backing layer and a pressure-sensitive adhesive layer disposed on at least one side of the backing layer, wherein the pressure-sensitive adhesive layer comprises a pressure-sensitive adhesive base, terbinafine and/or a pharmacologically acceptable salt thereof, and sodium acetate and/or sorbitan monolaurate as a solubilizer.

Abstract: A cover material adapted to cover the entirety of a patch is provided. The cover material has a support layer and, superimposed on a surface thereof, a pressure sensitive adhesive layer. The patch has a support film with a thickness of 12- to 30 ?m and, superimposed thereon, a drug containing layer. The cover material may be attached to the surface of the support film and to the skin around the patch so that the pressure sensitive adhesive layer is brought into contact with edges of the drug containing layer. Additionally, the pressure sensitive adhesive layer contains an adhesive resulting from the polymerization of vinyl acetate or N-vinyl-2-pyrrolidone and a C8 alkyl (meth)acrylate as essential monomers. Thus, there is provided a cover material that, when a patch medicated with, for example, mesylic acid pergolide is fixed on diseased part, such as, a part of the skin, by covering the patch, is capable of reducing irritation, etc. on the diseased part.

Abstract: It is intended to provide pergolide-containing transdermal preparations having reduced side effects and exerting sufficient therapeutic effects. Namely, a pergolide-containing transdermal preparation which is capable of achieving a plasma AUC ratio of pergolide or the like to at least one pergolide metabolite of 1:0.5 to 1:5; and/or transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof which is capable of achieving a ratio (A/B) of the maximum plasma level (A) of pergolide and/or a pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration of less than 2.

Abstract: The present invention provides a cover material 10, adapted to be attached to skin in a manner covering over the entirety of a patch 20, comprising a pressure-sensitive adhesive layer 12 on one side of a support 11, wherein said patch 20 comprises a drug-containing layer 22 for contacting with the skin, said layer being provided on a support film 21 with a thickness of 12-30 ?m, and wherein the cover material 10 is adapted to be attached to said support film 21 and a region of the skin around said patch 20 in such a manner that the pressure-sensitive adhesive layer 12 contacts with the edges of the drug-containing layer 22, and the pressure-sensitive adhesive layer 12 comprises a pressure-sensitive adhesive obtained by polymerizing vinyl acetate or N-vinyl-2-pyrrolidone and a (meth)acrylic acid alkyl ester with a C8 alkyl group as essential monomer components.

Abstract: It is intended to provide pergolide-containing transdermal preparations having reducreduced side effects and exerting sufficient therapeutic effects. Namely, a pergolide-containing transdermal preparation which is capable of achieving a plasma AUC ratio of pergolide or the like to at least one pergolide metabolite of 1:0.5 to 1:5; and/or transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof which is capable of achieving a ratio (A/B) of the maximum plasma level (A) of pergolide and/or a pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration of less than 2.

Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with an adhesive base agent and pergolide and/or a pharmaceutically acceptable salt thereof, wherein the adhesive base agent comprises an acrylic polymer including no substantial carboxyl group and hydroxyl group and having self-adhesion properties and a rubber polymer, and the weight ratio of the content of the acrylic polymer to the content of the rubber polymer is from 1:1 to 1:9.

Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylate—vinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.

Abstract: Percutaneous absorption preparations for treating dementia which contain an adhesive composition, characterized in that the adhesive composition contains the active ingredient in a dispersed state, the active ingredient is released at a pharmacologically effective rate and the skin permeation rate thereof is at least 1.2 &mgr;g/cm2/h. Thus, it is possible to provide percutaneous absorption preparations whereby the therapeutic effect can be sustained over a prolonged period of time without elevating the concentration of the active ingredient in the plasma to such a level as causing the expression of side effects in the administration of remedies for dementia.